His primary areas of investigation include Immunology, Interleukin 12, Cancer research, Cell culture and Genetic enhancement. In his study, which falls under the umbrella issue of Immunology, Sarcoma is strongly linked to Systemic administration. His study in Interleukin 12 is interdisciplinary in nature, drawing from both Spleen, CD8, Cytokine and Immunotherapy.
Hideaki Tahara has researched Cancer research in several fields, including Virus, Interleukin 18 and Toxicity. His Cell culture study combines topics in areas such as Immune system and Cytotoxicity. His work on Genetic enhancement is being expanded to include thematically relevant topics such as Viral vector.
Hideaki Tahara mainly investigates Cancer research, Immunology, Interleukin 12, Genetic enhancement and Immune system. Hideaki Tahara interconnects Cancer, CD8, Transfection, Lymphatic system and Antibody in the investigation of issues within Cancer research. His work deals with themes such as Cytotoxic T cell and In vivo, which intersect with Immunology.
In his research on the topic of Interleukin 12, Interferon is strongly related with Interleukin. The Genetic enhancement study combines topics in areas such as Cytokine, Virology, Molecular biology, Viral vector and Electroporation. As a part of the same scientific study, Hideaki Tahara usually deals with the Immune system, concentrating on Antigen and frequently concerns with Cancer immunotherapy.
The scientist’s investigation covers issues in Cancer research, Immunology, Internal medicine, Immune system and Antibody. Hideaki Tahara has included themes like Cancer cell, Apoptosis, CD8, Lymphatic system and Metastasis in his Cancer research study. Hideaki Tahara integrates Immunology and Advertising in his research.
His studies in Internal medicine integrate themes in fields like Diabetes mellitus, Diabetic mouse, Systemic administration and Oncology. Hideaki Tahara interconnects Cellular immunity, Cellular Immunology, In vivo and Mechanism of action in the investigation of issues within Antibody. His work deals with themes such as Interleukin 12, FOXP3, Bone marrow and Genetically modified organism, which intersect with Cancer immunotherapy.
Hideaki Tahara mostly deals with Immunology, Immune system, CD8, Antitumor immunity and Cancer. His Immunology study combines topics from a wide range of disciplines, such as Cancer cell and Molecular targeting. His Immune system study incorporates themes from Inflammation, Tumor progression, Stromal cell and Metastasis.
His study in CD8 is interdisciplinary in nature, drawing from both Central tolerance, Immune tolerance, Peripheral tolerance, Clonal deletion and Adoptive cell transfer. The study incorporates disciplines such as Alternative medicine, Translational research and Clinical trial in addition to Cancer. His Cancer immunotherapy research is multidisciplinary, incorporating elements of Immune checkpoint, Cancer research and IL-2 receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis
Hiroshi Oka;Hitoshi Shiozaki;Kenji Kobayashi;Masatoshi Inoue.
Cancer Research (1993)
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
C L Nastala;H D Edington;T G McKinney;H Tahara.
Journal of Immunology (1994)
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Michael B. Atkins;Michael J. Robertson;Michael Gordon;Michael T. Lotze.
Clinical Cancer Research (1997)
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Hideaki Tahara;Herbert J. Zeh;Walter J. Storkus;Itzhak Pappo.
Cancer Research (1994)
Viral vectors for gene therapy
Paul D. Robbins;Hideaki Tahara;Steven C. Ghivizzani.
Trends in Biotechnology (1998)
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Tadashi Osaki;Jean-Marie Péron;Quan Cai;Haruki Okamura.
Journal of Immunology (1998)
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
Yasuhiko Nishioka;Motohiro Hirao;Paul D Robbins;Michael T. Lotze.
Cancer Research (1999)
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
H. Tahara;L. Zitvogel;W. J. Storkus;H. J. Zeh.
Journal of Immunology (1995)
Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
R M Berman;T Suzuki;H Tahara;P D Robbins.
Journal of Immunology (1996)
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.
Tadamichi Suzuki;Hideaki Tahara;Satwant Narula;Kevin W. Moore.
Journal of Experimental Medicine (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: